Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report.

ABSTRACT: We present a case of a 43-year-old female patient with clinical stage IIIB (T3N2M0) anaplastic lymphoma kinase (ALK)-positive adenocarcinoma of the lung. Surgery was not performed initially because of multiple mediastinal lymph nodes invasion, although the mass was technically resected. With the assessment of upfront multidisciplinary consultation, administration of neoadjuvant crizotinib was selected to induce the downstaging and facilitate the subsequent surgical treatment. After 10 weeks of neoadjuvant crizotinib treatment, a partial response was achieved and the tumor could be radically resected. There were no sever toxic effects and treatment-related surgical delay during the whole neoadjuvant crizotinib therapy. The patient then successfully underwent video-assisted single port thora

SUBMITTER: Tian Y 

PROVIDER: S-EPMC7333158 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature